Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Neurobiology of Aging

• Publication date

  2006-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.NEUROBIOLAGING.2005.08.012PMID 16207501
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Precipitating Role for Truncated α-Synuclein and the Proteasome in α-Synuclein Aggregation

  2005cited by this paper
• Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

  2005cited by this paper
• Proteolysis: from the lysosome to ubiquitin and the proteasome

  2005cited by this paper
• Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up‐regulate iHSP70, following proteasomal inhibition

  2005cited by this paper
• Molecular pathophysiology of Parkinson's disease.

  2005cited by this paper
• Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress.

  2005cited by this paper
• α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease

  2005cited by this paper
• Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.

  2005cited by this paper
• Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition.

  2005cited by this paper
• Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.

  2005cited by this paper
• Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

  2005cited by this paper
• Modulation of neurodegeneration by molecular chaperones

  2005cited by this paper
• Proteasomal activity in brain differs between species and brain regions and changes with age.

  2005cited by this paper
• HSP27 but not HSP70 has a potent protective effect against α‐synuclein‐induced cell death in mammalian neuronal cells

  2004cited by this paper
• CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation

  2004cited by this paper
• Geldanamycin induces Hsp70 and prevents α-synuclein aggregation and toxicity in vitro

  2004cited by this paper
• Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

  2004cited by this paper
• Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective*

  2004cited by this paper
• How does Parkinson's disease begin? The role of compensatory mechanisms.

  2004cited by this paper
• Alteration in α‐synuclein mRNA expression in Parkinson's disease

  2004cited by this paper
• Proteasomes and their kin: proteases in the machine age

  2004cited by this paper
• Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation

  2004cited by this paper
• Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles.

  2004cited by this paper
• Inefficient degradation of truncated polyglutamine proteins by the proteasome

  2004cited by this paper
• Hsp70 Reduces α-Synuclein Aggregation and Toxicity*

  2004cited by this paper
• α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

  2004cited by this paper
• Pathogenetic mechanisms of parkin in Parkinson's disease.

  2004cited by this paper
• Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease

  2004cited by this paper
• Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro.

  2004cited by this paper
• Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Alpha-synuclein: normal function and role in neurodegenerative diseases.

  2004cited by this paper
• Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

  2004cited by this paper
• Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.

  2004cited by this paper
• Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.

  2004cited by this paper
• Inflammation and neurodegeneration in Parkinson's disease.

  2004cited by this paper
• Decreased proteolysis caused by protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 'aggresomes' during oxidative stress, aging, and disease.

  2004cited by this paper
• Pathway for Degradation of Peptides Generated by Proteasomes

  2004cited by this paper
• Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

  2004cited by this paper
• Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

  2004cited by this paper
• Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.

  2004cited by this paper
• Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins.

  2004cited by this paper
• Proteasomal inhibition by alpha-synuclein filaments and oligomers.

  2004cited by this paper
• Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1

  2004cited by this paper
• Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

  2004cited by this paper
• Alteration in alpha-synuclein mRNA expression in Parkinson's disease.

  2004cited by this paper
• Proteasome Inhibition Alters Neural Mitochondrial Homeostasis and Mitochondria Turnover*

  2004cited by this paper
• Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain.

  2004cited by this paper
• α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication

  2004cited by this paper
• Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications

  2004cited by this paper
• Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

  2004cited by this paper
• Proteasome inhibition increases DNA and RNA oxidation in astrocyte and neuron cultures

  2004cited by this paper
• Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity.

  2004cited by this paper
• Lewy-body formation is an aggresome-related process: a hypothesis.

  2004cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.

  2004cited by this paper
• Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes

  2004cited by this paper
• Proteasomal Inhibition by α-Synuclein Filaments and Oligomers*

  2004cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation.

  2003cited by this paper
• α-Synuclein Locus Triplication Causes Parkinson's Disease

  2003cited by this paper
• Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen‐dependent mechanism

  2003cited by this paper
• The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.

  2003cited by this paper
• Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function*

  2003cited by this paper
• Apoptosis in Parkinson's disease: Signals for neuronal degradation

  2003cited by this paper
• An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells

  2003cited by this paper
• Neuroinflammatory processes in Parkinson's disease

  2003cited by this paper
• Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies

  2003cited by this paper
• Protein degradation and protection against misfolded or damaged proteins

  2003cited by this paper
• The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.

  2003cited by this paper
• How the ubiquitin–proteasome system controls transcription

  2003cited by this paper
• Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.

  2003cited by this paper
• The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome

  2003cited by this paper
• Ubiquitin: not just for proteasomes anymore.

  2003cited by this paper
• Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1.

  2003cited by this paper
• α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

  2003cited by this paper
• Oxidative stress in Parkinson's disease

  2003cited by this paper
• Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein

  2003cited by this paper
• Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Emerging Role for Autophagy in the Removal of Aggresomes in Schwann Cells

  2003cited by this paper
• Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

  2003cited by this paper
• A missense mutation (L166P) in DJ‐1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo‐oligomerization

  2003cited by this paper
• Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies.

  2003cited by this paper
• Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease

  2003cited by this paper
• L166P Mutant DJ-1, Causative for Recessive Parkinson's Disease, Is Degraded through the Ubiquitin-Proteasome System*

  2003cited by this paper
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• Proteasomes and Molecular Chaperones : Cellular Machinery Responsible for Folding and Destruction of Unfolded Proteins

  2003cited by this paper
• Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein.

  2003cited by this paper
• Epidemiology of neurodegeneration.

  2003cited by this paper
• Altered proteasomal function in sporadic Parkinson's disease.

  2003cited by this paper
• Fine Structure and Biochemical Mechanisms Underlying Nigrostriatal Inclusions and Cell Death after Proteasome Inhibition

  2003cited by this paper
• Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.

  2003cited by this paper
• Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.

  2003cited by this paper
• Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein.

  2003cited by this paper
• Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons.

  2003cited by this paper
• Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein.

  2003cited by this paper
• Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function*

  2003cited by this paper
• Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease

  2003cited by this paper
• Proteasome inhibition causes nigral degeneration with inclusion bodies in rats

  2002cited by this paper

• Quantification of Protein Secondary Structures from Discrete Frequency Infrared Images Using Machine Learning

  2025cites this paper
• α-Synuclein-Assembled Synaptic Vesicle Pools at the Presynaptic Terminal: A Study of α-Synuclein Function Using a Novel Mouse Model

  2025cites this paper
• Cinnarizine, a Calcium Channel Blocker, Partially Prevents the Striatal Dopamine Decline and Loss of Nigral Dopamine Neurons in the Lactacystin-Induced Rat Model of Parkinson’s Disease

  2025cites this paper
• M14 substitutions in exanatide modulate alpha‐synuclein aggregation

  2025cites this paper
• Current Perspectives on Pathogenesis, Clinical Manifestations, and Treatment of Parkinson's Disease

  2025cites this paper
• α-Synuclein pathology as a target in neurodegenerative diseases

  2024cites this paper
• Translational molecular imaging and drug development in Parkinson’s disease

  2023cites this paper
• Alpha-synuclein oligomers alter the spontaneous firing discharge of cultured midbrain neurons

  2023cites this paper
• Prevalence of different types of wound infection in subjects with Parkinson's disease and total joint arthroplasty: A meta‐Analysis

  2023cites this paper
• MicroRNA-217-5p triggers dopaminergic neuronal degeneration via autophagy activation under Atrazine exposure.

  2023cites this paper
• Exploration of Protein Aggregations in Parkinson's Disease Through Computational Approaches and Big Data Analytics.

  2022cites this paper
• Evaluating the neuroprotective activities of vinpocetine, punicalagin, niacin and vitamin E against behavioural and motor disabilities of manganese-induced Parkinson's disease in Sprague Dawley rats.

  2022cites this paper
• COVID-19 and Parkinson’s Disease: Possible Links in Pathology and Therapeutics

  2022cites this paper
• Cocoa Extract Provides Protection against 6-OHDA Toxicity in SH-SY5Y Dopaminergic Neurons by Targeting PERK

  2022cites this paper
• Review of Metabolomics-Based Biomarker Research for Parkinson’s Disease

  2021cites this paper
• The effects of rigidity on energy expenditure during walking in Parkinson Disease

  2021cites this paper
• The effects of simulated parkinsonian rigidity on energy expenditure during gait

  2021cites this paper
• Neuroprotection and Neurorestoration of Nigra Striatal Dopamine Neurons by Novel Multitarget Drugs, M30

  2021cites this paper
• Genetic Pathways Involved in the Pathogenesis of Parkinson's Disease.

  2021cites this paper
• Sodium Butyrate Exacerbates Parkinson’s Disease by Aggravating Neuroinflammation and Colonic Inflammation in MPTP-Induced Mice Model

  2020cites this paper
• Mitochondrial biogenesis in organismal senescence and neurodegeneration.

  2020cites this paper
• Anxiety: An ignored aspect of Parkinson's disease lacking attention.

  2020cites this paper
• Mesenchymal Stem Cell Based Therapy for Parkinson's Disease

  2019cites this paper
• PERK-Mediated Unfolded Protein Response Activation and Oxidative Stress in PARK20 Fibroblasts

  2019cites this paper
• Effect of Parkinson's Disease on Primary Total Joint Arthroplasty Outcomes: A Meta-Analysis of Matched Control Studies.

  2019cites this paper
• Erythropoietin as a Modulator of Pathology in a Toxicant Mouse Model of Parkinson’s Disease

  2019cites this paper
• The deglycase activity of DJ‐1 mitigates &agr;‐synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ‐1 in Parkinson's disease

  2019cites this paper
• Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder

  2018cites this paper
• Neuroprotective effect of arctigenin against neuroinflammation and oxidative stress induced by rotenone

  2018cites this paper
• LncRNA-UCA1 promotes PD development by upregulating SNCA.

  2018cites this paper
• Effect of Natural Compounds Curcumin and Nicotinamide on α-synuclein Accumulation in a C. elegans Model of Parkinson’s Disease

  2018influential citation
• Copper Increases Brain Oxidative Stress and Enhances the Ability of 6-Hydroxydopamine to Cause Dopaminergic Degeneration in a Rat Model of Parkinson’s Disease

  2018cites this paper
• Evaluation of a computer game based rehabilitation system for assessment of balance and gait impairments in individuals with Parkinson’s disease

  2018cites this paper
• Real-time determination of aggregated alpha-synuclein induced membrane disruption at neuroblastoma cells using scanning ion conductance microscopy.

  2018cites this paper
• The SH-SY5Y cell line in Parkinson’s disease research: a systematic review

  2017cites this paper
• Autophagic modulation by rosuvastatin prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson's disease.

  2017cites this paper
• Copper increases the ability of 6‐hydroxydopamine to generate oxidative stress and the ability of ascorbate and glutathione to potentiate this effect: potential implications in Parkinson's disease

  2017cites this paper
• Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview.

  2017cites this paper
• Oral Health Issues and Challenges in Parkinson’s Disease

  2017cites this paper
• Plasma levels of miR-137 and miR-124 are associated with Parkinson’s disease but not with Parkinson’s disease with depression

  2017cites this paper
• MicroRNA-181a Regulates Apoptosis and Autophagy Process in Parkinson’s Disease by Inhibiting p38 Mitogen-Activated Protein Kinase (MAPK)/c-Jun N-Terminal Kinases (JNK) Signaling Pathways

  2017cites this paper
• α-Synuclein binds to cytoplasmic vesicles in U251 glioblastoma cells.

  2017cites this paper
• Carnosic Acid Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells by Inducing Autophagy Through an Enhanced Interaction of Parkin and Beclin1

  2016cites this paper
• Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson’s Disease

  2016cites this paper
• Investigation of motor and olfactory dysfunction in genetic and non-genetic animal models of Parkinson’s disease: implications for translational research in medicine

  2016cites this paper
• Down-regulation of p21-activated serine/threonine kinase 1 is involved in loss of mesencephalic dopamine neurons

  2016cites this paper
• Mitochondrial Translocation of High Mobility Group Box 1 Facilitates LIM Kinase 2-Mediated Programmed Necrotic Neuronal Death

  2016cites this paper
• MiR‐124 Regulates Apoptosis and Autophagy Process in MPTP Model of Parkinson's Disease by Targeting to Bim

  2016cites this paper
• Neuroprotective effect of modified Chungsimyeolda-tang, a traditional Korean herbal formula, via autophagy induction in models of Parkinson's disease.

  2015cites this paper
• Altered motor phenotype and dopamine transmission associated with mutations of the parkinsonian gene LRRK2

  2015cites this paper
• Protein Misfolding, Aggregation and Diseases

  2015influential citation
• Related factors and prevalence of Parkinson's disease among Uygur residents in Hetian, Xinjiang Uygur Autonomous Region.

  2015influential citation
• Molecular Mechanism Underlying PD Pathogenesis-A Possible Role for Sphingosine Kinases and Sphingosine-1-Phosphate

  2015cites this paper
• Upregulation of alphaB-crystallin expression in the substantia nigra of patients with Parkinson's disease.

  2015cites this paper
• The Natural Progression of Parkinson's Disease in a Small Cohort with 15 Drug-naïve Patients

  2015cites this paper
• Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein

  2015cites this paper
• Emerging therapies for Parkinson's disease: from bench to bedside.

  2014cites this paper
• Association of glycogen synthase kinase-3β with Parkinson’s disease (Review)

  2014cites this paper
• Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease.

  2013cites this paper
• The Costs and Benefits of Deep Brain Stimulation Surgery for Patients with Parkinson’s Disease at Different Stages of Severity – An Initial Exploration

  2013cites this paper
• Proteomics analysis of human brain tissue infected by street rabies virus

  2013cites this paper
• NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP.

  2013cites this paper
• Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain Stimulation

  2013cites this paper
• Role of Protein Aggregation in Neurodegenerative Diseases

  2013cites this paper
• Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson’s disease

  2013cites this paper
• Influence of methionine oxidation on the aggregation of recombinant human growth hormone.

  2013cites this paper
• Parkinson's disease management. Part II- discovery of MAO-B inhibitors based on nitrogen heterocycles and analogues.

  2012cites this paper
• Neuroprotection and Neuroregeneration in Alzheimer's Disease

  2012cites this paper
• Hormone Replacement Therapy and Risk for Neurodegenerative Diseases

  2012cites this paper
• The Aggregation of Huntingtin and α-Synuclein

  2012cites this paper
• Meta-analysis of the influence of Parkin p.Asp394Asn variant on the susceptibility of Parkinson's disease.

  2012cites this paper
• MPTP-induced model of Parkinson's disease in heat shock protein 70.1 knockout mice.

  2012cites this paper
• Radiating Amyloid Fibril Formation on the Surface of Lipid Membranes through Unit-Assembly of Oligomeric Species of α-Synuclein

  2012cites this paper
• α‐Synuclein oligomers oppose long‐term potentiation and impair memory through a calcineurin‐dependent mechanism: relevance to human synucleopathic diseases

  2012cites this paper
• M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.

  2012cites this paper
• A Mechanistic Study of Proteasome Inhibition-Induced Iron Misregulation in Dopamine Neuron Degeneration

  2012cites this paper
• Perfusion and metabolism imaging studies in Parkinson's disease.

  2012cites this paper
• Centrosomal aggregates and Golgi fragmentation disrupt vesicular trafficking of DAT.

  2012cites this paper
• Hsp90: structure and function.

  2012cites this paper
• Cysteine tagging for MS-based proteomics.

  2011cites this paper
• Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.

  2011cites this paper
• Characterizing the role of secretory phospholipase A₂ group IIA in glial cell-mediated neurotoxicity

  2011cites this paper
• Structural andT hermodynamic Studies of a-Synuclein Proteins Related to Parkinson’s Disease: Impact of Aqueous Solut

  2011cites this paper
• Does 1-(R)-aminoindan Possess Neuroprotective Properties Against Experimental Parkinson's Disease?

  2011cites this paper
• HMGB1 Acts on Microglia Mac1 to Mediate Chronic Neuroinflammation That Drives Progressive Neurodegeneration

  2011cites this paper
• Applications of fMRI to Neurodegenerative Disease

  2011cites this paper
• Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B

  2011cites this paper
• Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy.

  2011cites this paper
• Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation

  2011cites this paper
• Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.

  2011cites this paper
• The neuroprotective effect of modified Yeoldahanso-tang via autophagy enhancement in models of Parkinson's disease.

  2011cites this paper
• Antiparkinsonian Effects of Novel Adenosine A2A Receptor Antagonists

  2011cites this paper
• Disease-specific, neurosphere-derived cells as models for brain disorders

  2010cites this paper
• CSF markers of neurodegeneration in Parkinson’s disease

  2010cites this paper
• alpha-Synuclein overexpression during manganese-induced apoptosis in SH-SY5Y neuroblastoma cells.

  2010cites this paper
• Total Knee Arthroplasty and Parkinson Disease: Enhancing Outcomes and Avoiding Complications

  2010cites this paper
• Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI

  2010influential citation
• Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson’s Disease

  2010cites this paper
• Neurodegenerative Diseases: Exercising Toward Neurogenesis and Neuroregeneration

  2010cites this paper
• Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.

  2010cites this paper